A molecular model involving the membrane bilayer in the binding of lipid soluble drugs to their receptors in heart and brain.
Mason
R P
RP
Department of Radiology, University of Connecticut Health Center, Farmington 06032.
Moring
J
J
Herbette
L G
LG
D015060:1,2-Dipalmitoylphosphatidylcholine / Q000378:metabolism; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000378:metabolism; D017311:Amlodipine; D000818:Animals; D001921:Brain / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism; D004095:Dihydropyridines / Q000037:antagonists & inhibitors; D005782:Gels; D008051:Lipid Bilayers / Q000378:metabolism*; D008566:Membranes / Q000378:metabolism; D008956:Models, Chemical; D008958:Models, Molecular; D009206:Myocardium / Q000378:metabolism*; D009543:Nifedipine / Q000031:analogs & derivatives / Q000378:metabolism; D051381:Rats; D011955:Receptors, Drug / Q000378:metabolism*; D012508:Sarcolemma / Q000378:metabolism; D012995:Solubility
D004095:Dihydropyridines; D005782:Gels; D008051:Lipid Bilayers; D011955:Receptors, Drug; D017311:Amlodipine; D015060:1,2-Dipalmitoylphosphatidylcholine; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; C051102:BAY-P 8857; D002784:Cholesterol; D009543:Nifedipine